Desvenlafaxine Tablet, Extended Release
Product Images NDC 68071-5332

7 FDA label images from Nucare Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68071-5332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Image Description (Desvenlafaxine Tablets Structure)
Chemical structure of desvenlafaxine, showing its molecular components including phenol, cyclohexanol, dimethylamine group, and associated carboxylic acid moieties with water of hydration.*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

Image Description (Desvenlafaxine Tablets Figure 1)
A chart depicting geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of desvenlafaxine under conditions of renal and hepatic impairment, and by population subgroups including gender and age. The x-axis shows change relative to reference, ranging from 0.5 to 3.5.*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

Image Description (Desvenlafaxine Tablets Figure 2)
A pharmacokinetic bar plot showing the geometric mean ratio with 90% confidence intervals for the effect of Ketoconazole, a CYP3A4 inhibitor, on the Cmax and AUC parameters of a drug. The x-axis represents the change relative to reference, ranging from 0.50 to 2.0, with values showing an increase above 1.0 for both Cmax and AUC.*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

Image Description (Desvenlafaxine Tablets Figure 3)
A forest plot chart showing the geometric mean ratios and 90% confidence intervals for drug interactions involving Desvenlafaxine with various interacting drugs (Desipramine, Midazolam, Tamoxifen, and Aripiprazole). The chart compares pharmacokinetic parameters like Cmax and AUC relative to reference values to illustrate changes caused by Desvenlafaxine.*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

Image Description (Desvenlafaxine Tablets Figure 4)
A Kaplan-Meier survival curve showing the estimated proportion of patients with relapse over time in days from randomization for Desvenlafaxine 50 mg versus placebo. The graph compares relapse rates, with the x-axis representing time to relapse (days) and the y-axis showing the estimated proportion of patients experiencing relapse (%).*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

Image Description (Desvenlafaxine Tablets Figure 5)
A Kaplan-Meier survival curve chart showing the estimated proportion of patients with relapse over time (days from randomization) comparing Desvenlafaxine (blue solid line) versus placebo (red dashed line). The y-axis represents the estimated proportion of patients with relapse (%) and the x-axis represents time up to approximately 180 days.*
FDA Label Image

Jpg (68071 5332 3)

Jpg (68071 5332 3)
Label for Desvenlafaxine 50 mg extended-release tablets from NuCare Pharmaceuticals, Inc. The package contains 30 tablets. The label includes the NDC 68071-5332-3, product number R1915030, and notes that each film-coated tablet contains 76 mg Desvenlafaxine Succinate equivalent to 50 mg Desvenlafaxine. Storage instructions specify controlled temperature 68-77°F. The label also features lot, expiration, and serial number placeholders, a barcode, and a QR code with a note to contact FDA for side effect reporting.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.